PortfoliosLab logoPortfoliosLab logo
CVAC vs. BNTX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

CVAC vs. BNTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CureVac N.V. (CVAC) and BioNTech SE (BNTX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CVAC vs. BNTX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
CVAC
CureVac N.V.
3.10%32.55%-19.00%-30.18%-82.42%-57.68%45.03%
BNTX
BioNTech SE
-6.64%-16.45%7.97%-29.74%-40.40%216.24%18.76%

Fundamentals

EPS

CVAC:

$0.86

BNTX:

-$4.68

PS Ratio

CVAC:

14.83

BNTX:

7.52

Total Revenue (TTM)

CVAC:

$70.74M

BNTX:

$2.86B

Gross Profit (TTM)

CVAC:

$65.79M

BNTX:

$2.22B

EBITDA (TTM)

CVAC:

$181.23M

BNTX:

-$635.06M

Returns By Period

In the year-to-date period, CVAC achieves a 3.10% return, which is significantly higher than BNTX's -6.64% return.


CVAC

1D
0.00%
1M
0.00%
YTD
3.10%
6M
-13.54%
1Y
68.23%
3Y*
-12.56%
5Y*
-44.83%
10Y*

BNTX

1D
4.26%
1M
-19.37%
YTD
-6.64%
6M
-9.88%
1Y
-2.39%
3Y*
-10.64%
5Y*
-4.40%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


CureVac N.V.

BioNTech SE

Return for Risk

CVAC vs. BNTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CVAC
CVAC Risk / Return Rank: 8282
Overall Rank
CVAC Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
CVAC Sortino Ratio Rank: 8989
Sortino Ratio Rank
CVAC Omega Ratio Rank: 9494
Omega Ratio Rank
CVAC Calmar Ratio Rank: 7272
Calmar Ratio Rank
CVAC Martin Ratio Rank: 7474
Martin Ratio Rank

BNTX
BNTX Risk / Return Rank: 3737
Overall Rank
BNTX Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
BNTX Sortino Ratio Rank: 3737
Sortino Ratio Rank
BNTX Omega Ratio Rank: 3838
Omega Ratio Rank
BNTX Calmar Ratio Rank: 3636
Calmar Ratio Rank
BNTX Martin Ratio Rank: 3636
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CVAC vs. BNTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CureVac N.V. (CVAC) and BioNTech SE (BNTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CVACBNTXDifference

Sharpe ratio

Return per unit of total volatility

1.39

-0.05

+1.43

Sortino ratio

Return per unit of downside risk

2.70

0.29

+2.40

Omega ratio

Gain probability vs. loss probability

1.47

1.04

+0.43

Calmar ratio

Return relative to maximum drawdown

1.56

-0.21

+1.77

Martin ratio

Return relative to average drawdown

4.30

-0.43

+4.73

CVAC vs. BNTX - Sharpe Ratio Comparison

The current CVAC Sharpe Ratio is 1.39, which is higher than the BNTX Sharpe Ratio of -0.05. The chart below compares the historical Sharpe Ratios of CVAC and BNTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


CVACBNTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.39

-0.05

+1.43

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.64

-0.08

-0.56

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.48

0.43

-0.91

Correlation

The correlation between CVAC and BNTX is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Dividends

CVAC vs. BNTX - Dividend Comparison

Neither CVAC nor BNTX has paid dividends to shareholders.


TTM2025202420232022
CVAC
CureVac N.V.
0.00%0.00%0.00%0.00%0.00%
BNTX
BioNTech SE
0.00%0.00%0.00%0.00%2.43%

Drawdowns

CVAC vs. BNTX - Drawdown Comparison

The maximum CVAC drawdown since its inception was -98.30%, which is greater than BNTX's maximum drawdown of -82.08%. Use the drawdown chart below to compare losses from any high point for CVAC and BNTX.


Loading graphics...

Drawdown Indicators


CVACBNTXDifference

Max Drawdown

Largest peak-to-trough decline

-98.30%

-82.08%

-16.22%

Max Drawdown (1Y)

Largest decline over 1 year

-26.43%

-30.40%

+3.97%

Max Drawdown (5Y)

Largest decline over 5 years

-98.19%

-82.08%

-16.11%

Current Drawdown

Current decline from peak

-96.58%

-79.67%

-16.91%

Average Drawdown

Average peak-to-trough decline

-80.86%

-55.53%

-25.33%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.57%

15.03%

-5.46%

Volatility

CVAC vs. BNTX - Volatility Comparison

The current volatility for CureVac N.V. (CVAC) is 0.00%, while BioNTech SE (BNTX) has a volatility of 24.56%. This indicates that CVAC experiences smaller price fluctuations and is considered to be less risky than BNTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


CVACBNTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.00%

24.56%

-24.56%

Volatility (6M)

Calculated over the trailing 6-month period

20.04%

33.33%

-13.29%

Volatility (1Y)

Calculated over the trailing 1-year period

57.22%

50.44%

+6.78%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

71.63%

57.12%

+14.51%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

75.83%

77.11%

-1.28%

Financials

CVAC vs. BNTX - Financials Comparison

This section allows you to compare key financial metrics between CureVac N.V. and BioNTech SE. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00B6.00BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
54.13M
898.89M
(CVAC) Total Revenue
(BNTX) Total Revenue
Values in USD except per share items